# Efgartigimod iv PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efgartigimod-iv

> The next catalyst for efgartigimod iv, sponsored by ARGENX SE (ARGX), is its primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | efgartigimod iv |
| Codes |  |
| Sponsor | ARGENX SE (ARGX) https://sec-api.dev/companies/argx/catalysts |
| Indications | AChR-Ab Seropositive Generalized Myasthenia Gravis, [Lupus Nephritis](https://sec-api.dev/indications/lupus-nephritis), [Primary Immune Thrombocytopenia (ITP)](https://sec-api.dev/indications/primary-immune-thrombocytopenia-itp), [Generalized Myasthenia Gravis](https://sec-api.dev/indications/generalized-myasthenia-gravis), Immune Thrombocytopenia (ITP) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06298552 (A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor argenx; Results First Posted 2026-08-10." https://clinicaltrials.gov/study/NCT06298552

### July 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Lupus Nephritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05810948 (A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT05810948

### August 10, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06298552 (A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor argenx; Results First Posted 2026-08-10." https://clinicaltrials.gov/study/NCT06298552?tab=results

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04833894 (Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT04833894

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04833894 (Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT04833894

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis; MG.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07284420 (ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-07 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07284420

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis; MG.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07284420 (ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-07 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07284420

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Immune Thrombocytopenia (ITP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06544499 (A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06544499

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Immune Thrombocytopenia (ITP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06544499 (A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06544499

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07194850 (A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07194850

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07194850 (A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07194850

## Same indication

- [ALXN1720](https://sec-api.dev/pdufa/alxn1720) (AZN)
- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Efgartigimod iv or efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-iv-or-efgartigimod-ph20-sc) (ARGX)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [Empasiprubart iv](https://sec-api.dev/pdufa/empasiprubart-iv) (ARGX)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [FT819](https://sec-api.dev/pdufa/ft819) (FATE)
- [Gefurulimab](https://sec-api.dev/pdufa/gefurulimab) (AZN)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [Ianalumab s.c. q4w](https://sec-api.dev/pdufa/ianalumab-s-c-q4w) (NVS)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [Iptacopan (part 1)](https://sec-api.dev/pdufa/iptacopan-part-1) (NVS)
- [AUCATZYL (obecabtagene autoleucel)](https://sec-api.dev/pdufa/obecabtagene-autoleucel) (AUTL)
- [Pozelimab + cemdisiran](https://sec-api.dev/pdufa/pozelimab-cemdisiran) (REGN)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [Remibrutinib (blinded)](https://sec-api.dev/pdufa/remibrutinib-blinded) (NVS)
- [Sovleplenib](https://sec-api.dev/pdufa/sovleplenib) (HCM)
- [APRIL (telitacicept)](https://sec-api.dev/pdufa/telitacicept) (VOR)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efgartigimod-iv.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Efgartigimod iv PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efgartigimod-iv

```bibtex
@misc{secapidev_pdufa_efgartigimod_iv_20261116,
  title        = {Efgartigimod iv PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efgartigimod-iv}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efgartigimod_iv_20261116","title":"Efgartigimod iv PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efgartigimod-iv","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
